Progress toward the development of agents to modulate the cell cycle.

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Taxanes remain valuable in cancer therapy.
• Novel antimitotic agents are crucial for overcoming treatment resistance.
• Inhibition of cyclin-dependent kinases (Cdks) presents a promising therapeutic strategy for antiproliferative diseases.

Purpose of the Study:

• To review the progress of next-generation antimitotic agents in clinical trials.
• To highlight the potential of cyclin-dependent kinase (Cdk) inhibition as a therapeutic approach.
• To discuss the current clinical evaluation of novel Cdk inhibitors.

Main Methods:

• Review of current clinical trial data for antimitotic agents.
• Analysis of research on cyclin-dependent kinase (Cdk) inhibition mechanisms.
• Evaluation of the clinical status of specific Cdk inhibitors like Flavopiridol and UCN-01.

Main Results:

• Next-generation antimitotic agents, including novel Cdk inhibitors, are progressing through clinical trials.
• Flavopiridol and UCN-01 are continuing their clinical evaluation.
• Newer, more selective Cdk inhibitors are entering clinical assessment.

Conclusions:

• The field of antimitotic cancer therapy is evolving with new drug candidates.
• Cyclin-dependent kinase (Cdk) inhibition is a key area of development for antiproliferative treatments.
• The ongoing clinical evaluation of selective Cdk inhibitors holds promise for future cancer treatment strategies.